12V Stock Chart & Stats
€50.02
€0.18(0.36%)
At close: 4:00 PM EDT
€50.02
€0.18(0.36%)
Day’s Range― - ―
52-Week Range€24.40 - €52.72
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€3.06B
Enterprise Value€4.37K
Total Cash (Recent Filing)€485.23M
Total Debt (Recent Filing)€40.11M
Price to Earnings (P/E)31.4
Beta0.48
Next Earnings
Nov 10, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding80,390,730
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€49.44Price Target Upside-1.16% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.64
Revenue Forecast (FY)€512.71M
Bulls Say, Bears Say
Bulls Say
Revenue And Test Volume GrowthSustained double-digit growth in testing revenue and volume indicates broadening physician adoption and demand for Veracyte’s genomic diagnostics. Raised annual guidance reinforces the business’s ability to compound revenue over the next several quarters.
Margin Expansion And ProfitabilityHigher gross margins, strong adjusted EBITDA, and the move to sustained net profitability show operating leverage as testing volume scales. These improvements can support durable reinvestment in R&D and commercialization while strengthening internal cash generation.
Low Leverage And Strong Cash GenerationA lightly leveraged balance sheet and substantial cash generation give Veracyte flexibility to fund product launches, evidence development, and potential strategic investments without relying heavily on external financing. This improves resilience through changing reimbursement or demand conditions.
Bears Say
Moderating Growth And Historical VolatilityAlthough current performance is strong, slower growth and a history of losses and inconsistent cash flow indicate that profitability is not yet fully proven across cycles. A change in demand, reimbursement, or investment intensity could pressure the recent earnings trajectory.
Clinical, Guideline, And Reimbursement DependenceExpansion of Prosigna and Decipher depends partly on clinical validation, guideline adoption, and payer coverage. Delayed or unfavorable trial outcomes, recommendations, or reimbursement decisions could slow physician adoption and limit the revenue contribution of new indications.
Competition And Afirma Workflow RiskVeracyte must defend adoption against emerging diagnostic technologies while maintaining reliable sample processing. Competitive substitutes or recurring no-result issues could weaken test economics, reduce clinician confidence, and require additional spending on workflow improvements.
Veracyte News
12V FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was €24.40 and its highest was €52.72 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is €3.06B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on Jul 30, 2026. The company reported €0.467 earnings per share for the quarter, beating the consensus estimate of €0.355 by €0.113.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Overvalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.35.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 80,390,730 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of €0.467 in its last earnings report, beating expectations of €0.355. Following the earnings report the stock price went down -1.099%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in DE:12V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€49.44 (-1.16% Downside)
€49.44 (-1.16% Downside)
Blogger Sentiment
Bullish
DE:12V Sentiment 80%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €934.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.58%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
12V Company Deck
12V Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all DE:12V earnings summaries12V Stock 12 Month Forecast
Average Price Target
€49.44
▼(-1.16% Downside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―